Women experience a better long-term immune recovery and a better survival on HAART in Lao People's Democratic Republic

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Bastard, Mathieu ^a   Soulinphumy, Khamphang ^b   Phimmasone, Prasith ^c,d   Saadani, Ahmed Hassani ^e   Ciaffi, Laura ^e   Communier, Arlette ^e   Phimphachanh, Chansy ^f   Ecochard, René ^g,h,i   Etard, Jean François ^a,j  

^a EPICENTRE   (France)

^b Savannakhet Hospital   (Laos)

^c MAHOSOT HOSPITAL   (Laos)

^d Institut de la Francophonie pour la Medecine Tropicale   (Laos)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

^f Ministry of Health Centre for HIV   (Laos)

^g HOSPICES CIVILS DE LYON   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^j UNIVERSITÉ DE MONTPELLIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPETENCE; LAOS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; WOMEN'S HEALTH;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LAOS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84872470428     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-27     Document Type: Article

References (65)

1. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005, 41:376-385. 10.1086/431482, 16007536.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d' Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29. 10.1016/S0140-6736(03)13802-0, 12853195.
3. Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource-poor settings: the experience of medecins sans frontieres. Aids 2003, 17:1995-1997. 10.1097/00002030-200309050-00023, 12960837.
4. Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS drug access initiatives in Cote d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. Aids 2003, Suppl 3:S1-111.
5. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005, 41:217-224. 10.1086/431199, 15983918.
6. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, Paton NI, Phanuphak P, Pujari S, Vibhagool A, Wong WW, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG. The TREAT Asia HIV observational database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005, 38:174-179. 10.1097/01.qai.0000145351.96815.d5, 3070962, 15671802.
7. UN Joint Programme on HIV/AIDS Global Report 2010, Geneva: UNAIDS Report on the Global AIDS Epidemic, available at: http://www.unaids.org/documents/20101123_globalreport_em.pdf, UN Joint Programme on HIV/AIDS.
8. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet 2004, 364:69-82. 10.1016/S0140-6736(04)16593-8, 15234860.
9. National Committee for the Control of AIDS Lao PDR UNGASS Country Progress Report 2010 2010, Vientiane, National Committee for the Control of AIDS.
10. Sheridan S, Phimphachanh C, Chanlivong N, Manivong S, Khamsyvolsvong S, Lattanavong P, Sisouk T, Toledo C, Scherzer M, Toole M, van Griensven F. HIV prevalence and risk behaviour among men who have sex with men in Vientiane capital, Lao People's democratic republic, 2007. Aids 2009, 23:409-414. 10.1097/QAD.0b013e32831ef510, 19114858.
11. Chulalongkorn University, Lao PDR's Center for HIV/AIDS/STI and Family Health International Migration to Thailand and its Potential Contribution to an HIV Epidemic in Lao PDR 2005, Vientiane: With support from the United States Agency for International Development (USAID), Chulalongkorn University, Lao PDR's Center for HIV/AIDS/STI and Family Health International.
12. Phimphachanh C, Sayabounthavong K, Oula R. Report on HIV prevalence study among migrant workers at 8 border provinces of Lao PDR 2006, Center for HIV/AIDS/STI, Lao PDR.
13. Phimphachanh C, Sayabounthavong K. The HIV/AIDS/STI situation in Lao People's democratic republic. AIDS Educ Prev 2004, 16:91-99. 10.1521/aeap.16.3.5.91.35523, 15262568.
14. National Committee for the Control of AIDS National strategic and action plan on HIV/AIDS/STI 2006-2010 2006, Lao People's Democratic Republic: National Committee for the Control of AIDS, National Committee for the Control of AIDS.
15. Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, Fox K, Thanprasertsuk S, Mock PA, Ningsanond P, Lertpiriyasuwat C, Pinyopornpanich S. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009, 50:506-512. 10.1097/QAI.0b013e3181967602, 19223784.
16. Chaiwarith R, Salee P, Kotarathitithum W, Sirisanthana T, Supparatpinyo K. Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count. Curr HIV Res 2009, 7:340-345. 10.2174/157016209788347903, 19442132.
17. Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. Journal of acquired immune deficiency syndromes (1999) 2012, 60:91-8.
18. Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. Aids 2007, 21:351-359. 10.1097/QAD.0b013e328012c54f, 17255742.
19. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, Puertas G, Taburet AM, Ly N, Rouzioux C, Balkan S, Quillet C, Delfraissy JF. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. Aids 2007, 21:2293-2301. 10.1097/QAD.0b013e32828cc8b7, 18090277.
20. Pujades-Rodríguez M, Schramm B, Som L, Nerrienet E, Narom P, Chanchhaya N, Ferradini L, Balkan S. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Tropical medicine & international health: TM & IH 2011, 16:205-13. 10.1111/j.1365-3156.2010.02689.x, 3546997, 23342173.
21. Skrondal A, Rabe-Hesketh S. Generalized latent variable modeling/: multilevel, longitudinal and structural equation models 2004, Boca Raton, FL: Chapman & Hall/CRC.
22. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata 2008, College Station, TX: Stata Press, 2.
23. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, Schechter M, Laurent C, Keiser O, May M, Sprinz E, Egger M, Anglaret X. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008, 86:559-567. 10.2471/BLT.07.044248, 2647487, 18670668.
24. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007, 4:e298. 10.1371/journal.pmed.0040298, 2020494, 17941716.
25. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009, 4:e5790. 10.1371/journal.pone.0005790, 2686174, 19495419.
26. World Health Organization Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach 2003, Geneva: World Health Organization, World Health Organization.
27. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, Diakite N, Karcher S, Grundmann C, Marlink R, Dabis F, Anglaret X. Rapid scaling-up of antiretroviral therapy in 10,000 adults in cote d'Ivoire: 2-year outcomes and determinants. Aids 2008, 22:873-882. 10.1097/QAD.0b013e3282f768f8, 18427206.
28. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367:1335-1342. 10.1016/S0140-6736(06)68580-2, 16631912.
29. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Gueye NF, Gueye PM, Sow PS, Mboup S, Ndoye I, Ecochard R, Eric D. Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal. Am J Trop Med Hyg 2009, 80:1047-1053.
30. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, Egger M. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. Aids 2008, 22:2291-2302. 10.1097/QAD.0b013e3283121ca9, 2794130, 18981768.
31. Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, Falster K, Zhou J, Law MG. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: the Asia pacific HIV observational database (APHOD). J Acquir Immune Defic Syndr 2009, 50:513-520. 10.1097/QAI.0b013e31819906d3, 2752681, 19408354.
32. Lawn SD, Myer L, Bekker LG, Wood R. CD4 Cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006, 6:59. 10.1186/1471-2334-6-59, 1435908, 16551345.
33. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, Vecchiet J, D'Arminio Monforte A, Wu AW, Antinori A. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002, 31(Suppl 3):S123-7.
34. Bila B, Egrot M. Gender asymmetry in healthcare-facility attendance of people living with HIV/AIDS in Burkina Faso. Soc Sci Med 2009, 69:854-861. 10.1016/j.socscimed.2009.05.035, 19539415.
35. Desclaux A, Msellati P, Walentowitz S. Women, mothers and HIV care in resource-poor settings. Soc Sci Med 2009, 69:803-806. 10.1016/j.socscimed.2009.05.036, 19577832.
36. Bastard M, Fall MB, Laniece I, Taverne B, Desclaux A, Ecochard R, Sow PS, Delaporte E, Etard JF. Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. J Acquir Immune Defic Syndr 2011, 57:55-61. 10.1097/QAI.0b013e318211b43b, 21775934.
37. Le Coeur S, Collins IJ, Pannetier J, Lelievre E. Gender and access to HIV testing and antiretroviral treatments in Thailand: why do women have more and earlier access?. Soc Sci Med 2009, 69:846-853. 10.1016/j.socscimed.2009.05.042, 19573965.
38. Portelli MS, Tenni B, Kounnavong S, Chanthivilay P. Barriers to and facilitators of adherence to antiretroviral therapy among people living with HIV in Lao PDR: a qualitative study 2012, Asia-Pacific: Journal of public health/Asia-Pacific Academic Consortium for Public Health.
39. Remien RH, Chowdhury J, Mokhbat JE, Soliman C, Adawy ME, El-Sadr W. Gender and care: access to HIV testing, care, and treatment. J Acquir Immune Defic Syndr 2009, 51(Suppl 3):S106-10. 2793673, 19553777.
40. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, Schechter M, Tuboi SH, Sprinz E, Miotti P, Hosseinipour M, May M, Egger M, Bangsberg DR, Low N. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008, 17:47-55.
41. Mair C, Hawes SE, Agne HD, Sow PS, N'Doye I, Manhart LE, Fu PL, Gottlieb GS, Kiviat NB. Factors associated with CD4 lymphocyte counts in HIV-negative Senegalese individuals. Clin Exp Immunol 2008, 151:432-440. 10.1111/j.1365-2249.2007.03573.x, 2276971, 18190600.
42. Srikantiah P, Ghidinelli M, Bachani D, Chasombat S, Daoni E, Mustikawati DE, Nhan do T, Pathak LR, San KO, Vun MC, Zhang F, Lo YR, Narain JP. Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia pacific region. Aids 2010, 24(Suppl 3):S62-71. 10.1097/01.aids.0000390091.45435.ea, 20926930.
43. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, Gundersen SG, Bruun JN. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008, 8:52. 10.1186/1471-2334-8-52, 2364629, 18430196.
44. Sieleunou I, Souleymanou M, Schonenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-north province Cameroon. Trop Med Int Health 2009, 14:36-43.
45. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, Harries AD. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. Aids 2006, 20:2355-2360. 10.1097/QAD.0b013e32801086b0, 17117022.
46. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Aids 2008, 22:1897-1908. 10.1097/QAD.0b013e32830007cd, 18784453.
47. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. Aids 2006, 20:1181-1189. 10.1097/01.aids.0000226959.87471.01, 16691070.
48. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama 2006, 296:782-793. 10.1001/jama.296.7.782, 16905784.
49. Dabis F, Balestre E, Braitstein P, Miotti P, Brinkhof WG, Schneider M, Schechter M, Laurent C, Boulle A, Kabugo C, Capkun G, Seyler C, McIntyre J, Sprinz E, Bangsberg D, Van der Borght S, Egger M. Cohort profile: antiretroviral therapy in lower income countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005, 34:979-986.
50. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
51. Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, Karamagi CA. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of the AIDS support organization (TASO), Kampala Uganda. BMC Health Serv Res 2008, 8:241. 10.1186/1472-6963-8-241, 2606686, 19021908.
52. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected south African adults. J Acquir Immune Defic Syndr 2006, 43:78-84. 10.1097/01.qai.0000225015.43266.46, 16878045.
53. Srasuebkul P, Lim PL, Lee MP, Kumarasamy N, Zhou J, Sirisanthana T, Li PC, Kamarulzaman A, Oka S, Phanuphak P, Vonthanak S, Merati TP, Chen YM, Sungkanuparph S, Tau G, Zhang F, Lee CK, Ditangco R, Pujari S, Choi JY, Smith J, Law MG. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis 2009, 48:940-950. 10.1086/597354, 2758295, 19226231.
54. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids 2007, 21:1185-1197. 3460385, 17502729.
55. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholie S, Anglaret X. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in west Africa. Aids 2007, 21:2483-2491. 10.1097/QAD.0b013e3282f09876, 18025885.
56. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in south Africa. Aids 2009, 23:335-342. 10.1097/QAD.0b013e328321823f, 19114870.
57. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, King CC, Wang JD. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008, 13:513-519. 10.1111/j.1365-3156.2008.02029.x, 18282238.
58. Thai S, Koole O, Un P, Ros S, De Munter P, Van Damme W, Jacques G, Colebunders R, Lynen L. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009, 14:1048-1058. 10.1111/j.1365-3156.2009.02334.x, 19573140.
59. Zachariah R, Harries K, Moses M, Manzi M, Line A, Mwagomba B, Harries AD. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health 2009, 14:713-721. 10.1111/j.1365-3156.2009.02291.x, 19497082.
60. DeSilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, Cha SS. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 2009, 21:70-77. 10.1080/09540120802017636, 2849645, 19085222.
61. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. Aids 2006, 20:1163-1169. 10.1097/01.aids.0000226957.79847.d6, 16691068.
62. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, Ewald T, Mugusi F, Mtasiwa D, Fawzi W. Gender differences in antiretroviral treatment outcomes among HIV-infected adults in Dar es salaam, Tanzania. Aids 2011, 25. Ahead of print.
63. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L. Gender differences in survival among adult patients starting antiretroviral therapy in south Africa: a multicentre cohort study. PLoS medicine 2012, 9:e1001304. 10.1371/journal.pmed.1001304, 3433409, 22973181.
64. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a south African antiretroviral therapy programme. Trop Med Int Health 2009, 14:722-731. 10.1111/j.1365-3156.2009.02290.x, 2771267, 19413745.
65. Brinkhof MWG, Spycher BD, Yiannoutsos C, Weigel R, Wood R, Messou E, Boulle A, Egger M, Sterne JAC, . for the International epidemiological Database to Evaluate A Adjusting mortality for loss to follow-Up: analysis of five ART programmes in Sub-Saharan Africa. PLoS One 2010, 5:e14149. 10.1371/journal.pone.0014149, 2994756, 21152392, for the International epidemiological Database to Evaluate A.